Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

The stock's fall snapped a three-day winning streak.

Bristol Myers Squibb Co. annual cash flow and in depth look at BMY operating, investing, and financing activities.